ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Ofev Study Results Released of Fibrotic Progression in Patients with IPF
americanpharmaceuticacreview
November 13, 2017Boehringer Ingelheim announced results from a descriptive Phase IIIb lung imaging study providing evidence for the first time that Ofev (nintedanib) slowed the fibrotic process versus placebo in people with idiopathic pulmonary fibrosis (IPF).
Pharma Sources Insight July 2025
